Stock Analiz

Sangrix Inc. SGRX

Finance: Consumer Services · IPO 2019 · data as of November 13, 2026

$0.36Market cap $131806
Open the interactive analysis →

Sangrix Inc. (SGRX) is a financial company listed in the US with a market value of about $131806.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -112%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 98% below the current price.

About Sangrix

Sangrix is listed in the US and classified in finance: consumer services, IPO year 2019. Revenue went from $63M in 2017 to $39495 in 2025, a decline of about 60.2% a year. It was profitable in 4 of the last 10 years in our data.

Score: 0.8 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B0.0
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−98%

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-4387.4%
ROIC (5-yr avg.)-111.7%
Profitable years (of last 10)4
Years paying a dividend—

Financials, last 10 years

Fiscal year2026202520242023202220212020201920182017
Revenue—$39495$3M$6M$6M$80M$24M$99M$101M$63M
Net income-$24M-$7M-$18M-$28M$3M-$46M-$5M$4M$4M$2M
Free cash flow———-$7M-$23M—-$7M-$5M-$4M-$3M
EPS (diluted)$-65.71$-17.95$-48.15$-77.49$8.90$-125.26$-13.39$11.98$10.35$6.74
Net margin—-16543.8%-606.9%-450.7%51.7%-56.7%-20.1%4.4%3.7%3.9%
ROIC-200.7%-18.7%-93.7%-180.9%-64.5%-32.3%-9.1%-1.7%31.3%25.6%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Sangrix stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 98% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Sangrix pay a dividend?

Not currently.

Is Sangrix a good stock to buy?

We do not give buy or sell advice. Sangrix scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.